Liraglutide
Useful mainly for adults with type 2 diabetes and/or obesity (Saxenda also approved for adolescents 12+ with obesity) under a prescriber.
Prescription medication — not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only — it is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with type 2 diabetes and/or obesity (Saxenda also approved for adolescents 12+ with obesity) under a prescriber
Common dosing range
Diabetes: titrated to 1.2-1.8 mg once daily; weight management: titrated to 3.0 mg once daily
When to expect effects
Glucose lowering within weeks; weight loss over months
Watch out for
Boxed warning for thyroid C-cell tumors (rodent medullary thyroid carcinoma); risk of pancreatitis
What is it
Liraglutide is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist that boosts glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. It is given by daily subcutaneous injection. It is FDA-approved for type 2 diabetes (Victoza), for chronic weight management (Saxenda), and to reduce cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
type 2 diabetes glycemic control Strong Evidence | HbA1c reduction of roughly 1.0-1.5% versus placebo or active comparators | Adults with type 2 diabetes inadequately controlled on diet or other agents | Weeks |
chronic weight management in obesity Strong Evidence | About 8% mean body-weight reduction versus ~2.6% with placebo at 56 weeks (SCALE) | Adults with obesity or overweight with a weight-related condition | Months |
cardiovascular event reduction in type 2 diabetes Strong Evidence | About 13% relative reduction in major adverse cardiovascular events versus placebo (LEADER) | Adults with type 2 diabetes and high cardiovascular risk or established disease | Months to years |
type 2 diabetes glycemic control
- Effect
- HbA1c reduction of roughly 1.0-1.5% versus placebo or active comparators
- Best fit
- Adults with type 2 diabetes inadequately controlled on diet or other agents
- Time
- Weeks
chronic weight management in obesity
- Effect
- About 8% mean body-weight reduction versus ~2.6% with placebo at 56 weeks (SCALE)
- Best fit
- Adults with obesity or overweight with a weight-related condition
- Time
- Months
cardiovascular event reduction in type 2 diabetes
- Effect
- About 13% relative reduction in major adverse cardiovascular events versus placebo (LEADER)
- Best fit
- Adults with type 2 diabetes and high cardiovascular risk or established disease
- Time
- Months to years
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
type 2 diabetes glycemic control
Biomarker supportThe phase-3 LEAD program randomized adults with type 2 diabetes and showed liraglutide reduced HbA1c by about 1.0-1.5% with weight loss and low intrinsic hypoglycemia risk, performing favorably against comparators including glimepiride and insulin glargine on combined glycemic and weight endpoints. These trials supported approval for type 2 diabetes as Victoza.
Bottom line: Liraglutide reliably lowers HbA1c with modest weight loss in type 2 diabetes.
chronic weight management in obesity
Disease adjunctIn the phase-3 SCALE Obesity and Prediabetes trial, adults without diabetes who received liraglutide 3.0 mg daily with lifestyle intervention lost about 8% of body weight versus roughly 2.6% with placebo over 56 weeks, with more participants achieving 5% and 10% loss. A separate SCALE trial supported benefit in type 2 diabetes. Weight is regained after discontinuation, consistent with chronic-disease treatment.
Bottom line: At the 3.0 mg dose, liraglutide produces moderate, clinically meaningful weight loss while treatment continues.
cardiovascular event reduction in type 2 diabetes
Disease adjunctThe LEADER trial randomized adults with type 2 diabetes at high cardiovascular risk to liraglutide or placebo and found about a 13% relative reduction in the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, with a significant reduction in cardiovascular and all-cause death. This outcome trial underpins the cardiovascular risk-reduction indication for Victoza.
Bottom line: Liraglutide reduces major cardiovascular events and cardiovascular death in higher-risk type 2 diabetes.
How to take it
What to track
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Boxed warning: thyroid C-cell tumors, including medullary thyroid carcinoma, in rodents (human relevance unknown)
Acute pancreatitis
Gallbladder disease (cholelithiasis, cholecystitis)
Acute kidney injury from dehydration with severe GI symptoms
Severe hypoglycemia when combined with insulin or sulfonylureas
Increased heart rate
Who should avoid it
- People with a personal or family history of medullary thyroid carcinoma
- People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- People with prior serious hypersensitivity to liraglutide
- People with a history of pancreatitis (use with caution)
- Pregnant individuals
Pregnancy & breastfeeding
Not recommended in pregnancy; discontinue when pregnancy is recognized as weight loss offers no benefit and safety is not established.
Interactions
Additive glucose lowering raises hypoglycemia risk; doses of these often need reduction
Delayed gastric emptying can alter the rate/extent of absorption of co-administered oral drugs
Changed gastric emptying may affect absorption; monitor INR or drug levels
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
References by claim
type 2 diabetes glycemic control
chronic weight management in obesity
cardiovascular event reduction in type 2 diabetes
Marso et al., 2016 — PMC (2016) link
Track Liraglutide with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.